Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tibet AIM Pharm. Inc. (002826.SZ)
Beijing, CN
Headquartered in Beijing, China, Tibet AIM Pharm. Inc. was established in 2003 to conduct research and develop medical products across China. The company's diverse pharmaceutical portfolio targets a range of health conditions. Among its offerings are Miglitol tablets for managing diabetes and Gualoupi injection, prescribed for coronary disease. It also provides Oxytocin injection for gynecological and obstetric applications, alongside Carbetocin injections. A significant product is NalMefene injection, which is employed for treating various acute toxicities, such as those from alcohol, organic phosphorus, carbon monoxide, sedative-hypnotics, and opioid substances. Furthermore, it is indicated for serious infections, shock, syncope, and certain neurological issues. Completing its product line are Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, with therapeutic areas also extending to anti-infective, anti-allergic, and digestive system treatments.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.49% | -0.45% | -8.76% | -17.05% | -6.16% | -3.10% | +46.22% | +60.45% | +97.89% | +104.01% | +104.01% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-2.4% Q1'26: +22.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+100.0% ★ Q1'26: +10.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+18.6% ★ Q1'26: +43.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+18.0% ★ Q1'26: +13.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+32.4% ★ Q1'26: +38.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.8% Q1'26: -5.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.08× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
|---|---|---|
| Revenue |
488.77M
est: 935.67M (-47.8%)
|
553.26M
est: 1.37B (-59.6%)
|
| EBITDA |
39.90M
est: 95.44M (-58.2%)
|
61.44M
est: 139.83M (-56.1%)
|
| EBIT |
30.43M
est: 65.33M (-53.4%)
|
50.52M
est: 95.72M (-47.2%)
|
| Net Income |
25.26M
|
37.33M
|
| SGA |
131.93M
est: 327.23M (-59.7%)
|
147.97M
est: 479.43M (-69.1%)
|
| EPS |
0.13
|
0.20
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Huaming Jiang | Deputy General Manager | — | male |
| Jing Sheng Cui | Deputy General Manager | — | male |
| Lian Yang | Deputy General Manager | — | female |
| Qianjin Li | Deputy GM & Secretary of the Board of Directors | — | female |
| Ying Gao | Deputy General Manager | — | female |
| Yongxiang Zhang | Accounting Supervisor | — | — |
| Zhou Min | GM, Chief Financial Officer & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002826.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
